Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study

the Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS)

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Introduction: Previously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI-DS) and Alzheimer's disease (DS-AD) from those cognitively stable (CS). Methods: Data were analyzed on n = 305 (n = 225 CS; n = 44 MCI-DS; n = 36 DS-AD) enrolled in the Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS). Results: Distinguishing MCI-DS from CS, the serum profile produced an area under the curve (AUC) = 0.95 (sensitivity [SN] = 0.91; specificity [SP] = 0.99) and an AUC = 0.98 (SN = 0.96; SP = 0.97) for plasma when using an optimized cut-off score. Distinguishing DS-AD from CS, the serum profile produced an AUC = 0.93 (SN = 0.81; SP = 0.99) and an AUC = 0.95 (SN = 0.86; SP = 1.0) for plasma when using an optimized cut-off score. AUC remained unchanged to slightly improved when age and sex were included. Eotaxin3, interleukin (IL)-10, C-reactive protein, IL-18, serum amyloid A, and FABP3 correlated fractions at r2> = 0.90. Discussion: Proteomic profiles showed excellent detection accuracy for MCI-DS and DS-AD.

Original languageEnglish
Article numbere12039
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume12
Issue number1
DOIs
StatePublished - 2020

Fingerprint

Dive into the research topics of 'Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study'. Together they form a unique fingerprint.

Cite this